Direct-acting Antivirals Improved the Quality of Life, Ameliorated Disease-related Symptoms, and Augmented Muscle Volume Three Years Later in Patients with Hepatitis C Virus

Ichikawa, Tatsuki; Miyaaki, Hisamitsu; Miuma, Satoshi; Motoyoshi, Yasuhide; Yamashima, Mio; Yamamichi, Shinobu; Koike, Makiko; Nakano, Yusuke; Honda, Tetsurou; Yajima, Hiroyuki; Uehara, Ryouhei; Miyazaki, Osamu; Kuribayashi, Yasutaka; Kira, Keiji; Taura, Naota; Nakao, Kazuwa

doi:10.2169/internalmedicine.5102-20

Cited by 14 publications

(17 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results we observed in this cohort in Ukraine were similar to or of greater magnitude than those reported from other settings [ 6 , 14 – 16 ]. In a Japanese cohort, the only domain of the MOS SF-36 that was found to be significantly improved was general health perception, with an improvement of 3.81 that persisted at 3 years after treatment with DAA [ 6 ].…”

Section: Discussionsupporting

confidence: 89%

Impact of direct-acting antiviral treatment of hepatitis C on the quality of life of adults in Ukraine

Benade

Rosen

Antoniak³

et al. 2022

BMC Infect Dis

View full text Add to dashboard Cite

Background Direct-acting antivirals (DAAs) are highly effective in achieving sustained virologic response among those with chronic hepatitis C virus (HCV) infection. Quality of life (QOL) benefits for an HCV-infected population with high numbers of people who inject drugs and people living with HIV (PLHIV) in Eastern Europe have not been explored. We estimated such benefits for Ukraine. Methods Using data from a demonstration study of 12-week DAA conducted in Kyiv, we compared self-reported QOL as captured with the MOS-SF20 at study entry and 12 weeks after treatment completion (week 24). We calculated domain scores for health perception, physical, role and social functioning, mental health and pain to at entry and week 24, stratified by HIV status. Results Among the 857 patients included in the final analysis, health perception was the domain that showed the largest change, with an improvement of 85.7% between entry and week 24. The improvement was larger among those who were HIV negative (104.4%) than among those living with HIV (69.9%). Other domains that showed significant and meaningful improvements were physical functioning, which improved from 80.5 (95% CI 78.9–82.1) at study entry to 89.4 (88.1–90.7) at 24 weeks, role functioning (64.5 [62.3–66.8] to 86.5 [84.9–88.2]), social functioning (74.2 [72.1–76.2] to 84.8 [83.2–86.5]) and bodily pain (70.1 [68.2–72.0] to 89.8 [88.5–91.1]). Across all domains, QOL improvements among PLHIV were more modest than among HIV-negative participants. Conclusion QOL improved substantially across all domains between study entry and week 24. Changes over the study period were smaller among PLHIV.

show abstract

Section: Discussionsupporting

confidence: 89%

Impact of direct-acting antiviral treatment of hepatitis C on the quality of life of adults in Ukraine

Benade

Rosen

Antoniak³

et al. 2022

BMC Infect Dis

View full text Add to dashboard Cite

show abstract

“…Adipose tissue is considered as an important endocrine organ which releases biologically active polypeptides including adipose tissue specific adipokines like leptin and adiponectin and non-adipose tissue specific adipokines such as plasminogen activator inhibitor I (PAI-1)[ 55 ]. Adiponectin (an insulin-sensitizing hormone in muscle and liver) and leptin are most abundant in subcutaneous fat while PAI-1 is found in high levels in extracellular matrix[ 56 , 57 ]. Together, leptin, adiponectin and PAI-1 are the abundant adipokines which regulate the body lipid and glucose metabolism via the adipo-insular axis[ 58 ].…”

Section: Hepatitis C Virus Infection and Adipose Tissuementioning

confidence: 99%

Metabolic complications of hepatitis C virus infection

Chaudhari

Fouda

Sainu³

et al. 2021

WJG

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infection is a systemic disease that is implicated in multiple extrahepatic organ dysfunction contributing to its protean manifestations. HCV is associated with diverse extrahepatic disorders including atherosclerosis, glucose and lipid metabolic disturbances, alterations in the iron metabolic pathways, and lymphoproliferative diseases over and above the traditional liver manifestations of cirrhosis and hepatocellular carcinoma. The orchestration between HCV major proteins and the liver-muscle-adipose axis, poses a major burden on the global health of human body organs, if not adequately addressed. The close and inseparable associations between chronic HCV infection, metabolic disease, and cardiovascular disorders are specifically important considering the increasing prevalence of obesity and metabolic syndrome, and their economic burden to patients, the healthcare systems, and society. Cellular and molecular mechanisms governing the interplay of these organs and tissues in health and disease are therefore of significant interest. The coexistence of metabolic disorders and chronic hepatitis C infection also enhances the progression to liver fibrosis and hepatocellular carcinoma. The presence of metabolic disorders is believed to influence the chronicity and virulence of HCV leading to liver disease progression. This comprehensive review highlights current knowledge on the metabolic manifestations of hepatitis C and the potential pathways in which these metabolic changes can influence the natural history of the disease.

show abstract

“…The results we observed in this cohort in Ukraine were similar to or of greater magnitude than those reported from other settings. 5,13–15 In a Japanese cohort, the only domain of the MOS SF-36 that was found to be significantly improved was general health perception, with an improvement of 3.81 that persisted at 3 years after treatment with DAA. 5 Younossi et al found similarly that statistically significant, modest improvements in reported QOL were sustained as long as 2 years after SVR was achieved in U.S. patients.…”

Section: Discussionmentioning

confidence: 98%

“…5,13–15 In a Japanese cohort, the only domain of the MOS SF-36 that was found to be significantly improved was general health perception, with an improvement of 3.81 that persisted at 3 years after treatment with DAA. 5 Younossi et al found similarly that statistically significant, modest improvements in reported QOL were sustained as long as 2 years after SVR was achieved in U.S. patients. 16 The larger improvements we observed may reflect our relatively short follow up period (24 weeks after treatment initiation) and the fact that our study was conducted in a middle income country, rather than high income, and among many patients with co-morbidities; our participants had worse baseline domain scores and thus more room for HCV treatment to improve their QOL.…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

Impact of direct-acting antiviral treatment of hepatitis C on the quality of life of adults in Ukraine

Benade¹,

Rosen²,

Antoniak³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background Direct-acting antivirals (DAAs) are highly effective in achieving sustained virologic response among those with chronic hepatitis C virus (HCV) infection. Quality of life (QOL) benefits for an HCV-infected population with high numbers of people who inject drugs and people living with HIV (PLHIV) in Eastern Europe have not been explored. We estimated such benefits for Ukraine. Methods Using data from a demonstration study of 12-week DAA conducted in Kyiv, we compared self-reported QOL as captured with the MOS-SF20 at study entry and 12 weeks after treatment completion (week 24). We calculated domain scores for health perception, physical, role and social functioning, mental health and pain to at entry and week 24, stratified by HIV status. Results Among the 857 patients included for the final analysis, health perception was the domain that showed the largest change, with an improvement of 85.7% between entry and week 24. The improvement was larger among those who were HIV negative (104.4%) compared to those living with HIV (69.9%). Other domains that showed significant and meaningful improvements were physical functioning, which improved from 80.5 (95% CI: 78.9-82.1) at study entry to 89.4 (88.1-90.7) at 24 weeks, role functioning (64.5 [62.3-66.8] to 86.5 [84.9-88.2], social functioning (74.2 [72.1-76.2] to 84.8 [83.2-86.5] and bodily pain (70.1 [68.2-72.0] to 89.8 [88.5-91.1]). Across all domains, QOL improvements among PLHIV were more modest than among HIV-negative participants. Conclusion QOL improved substantially across all domains between study entry and week 24. Changes over the study period were smaller among PLHIV

show abstract

Direct-acting Antivirals Improved the Quality of Life, Ameliorated Disease-related Symptoms, and Augmented Muscle Volume Three Years Later in Patients with Hepatitis C Virus

Cited by 14 publications

References 30 publications

Impact of direct-acting antiviral treatment of hepatitis C on the quality of life of adults in Ukraine

Impact of direct-acting antiviral treatment of hepatitis C on the quality of life of adults in Ukraine

Metabolic complications of hepatitis C virus infection

Impact of direct-acting antiviral treatment of hepatitis C on the quality of life of adults in Ukraine

Contact Info

Product

Resources

About